US: Nestle acquires brain health nutrition business Pamlab
Nestle's health science division has acquired US-based Pamlab as part of the company's startegy to expand its presence in medical nutrition.
Nestle said yesterday (26 February) that it has bought Pamlab for an undisclosed fee.
The Swiss food giant runs its health science division as a fully owned subsidiary and has spent the past year building its presence in the area of medical nutrition.
Pamlab produces a range of "medical food products for use under medical supervision in the nutritional management of patients with mild cognitive impairment, depression and diabetic peripheral neuropathy", Nestle said.
One of its products, Metanx, helps to regulate metabolic processes associated with brain health in diabetes patients. It also makes Deplin, which is used to provide nutritional support for those taking antidepressants.
In 2012, Nestlé Health Science agreed to form a 50/50 joint venture named Nutrition Science Partners Ltd, to develop nutritional and medicinal products derived from plants to address gastrointestinal disorders. The transaction is still subject to regulatory approval.
New US acquisition for Nestlé Health Science will strengthen Brain Health and Metabolic Health portfolios with new medical foods
Nestlé Health Science, a fully owned subsidiary of Nestlé, has agreed to acquire the business of Pamlab, a US-based company with an innovative portfolio of medical food products for use under medical supervision in the nutritional management of patients with mild cognitive impairment, depression and diabetic peripheral neuropathy.
The acquisition further strengthens Nestlé Health Science’s capacity to deliver personalised healthcare to address chronic medical conditions through nutrition, especially in the areas of metabolic health and brain health.
“The acquisition of the Pamlab business is aligned with our strategic ambition to provide science-based nutritional solutions for people with chronic medical conditions. Pamlab will particularly strengthen our brain health platform and provide us an additional foothold in metabolic health in the US,” said Luis Cantarell, Nestlé Health Science President and Chief Executive Officer.
“By leveraging our nutrition heritage and US operations with Pamlab’s proven expertise in medical foods and strong sales force capabilities, together we can play a key role in helping to manage certain chronic diseases and improve the quality of patients’ lives,” he added.
Commercialised products that improve quality of life
Pamlab’s portfolio of prescription medical food products for use under medical supervision includes Metanx, one of their key products that is formulated to meet the distinct nutritional requirements of patients with diabetes to help restore the metabolic processes associated with peripheral neuropathy.
This serious condition is common among those with Type 2 Diabetes, where the patient’s peripheral blood flow has been compromised and their nerves damaged.
Pamlab also makes Deplin, a medical food specifically formulated to provide necessary nutritional support for certain people on prescribed antidepressant therapy for clinical depression.
Deplin contains l-methylfolate, the active ingredient of folate, to help balance three neurotransmitters associated with mood: serotonin, dopamine and norepinephrine.
In addition, the company produces CerefolinNAC, a medical food to help address distinct metabolic nutritional needs associated with mild cognitive impairment.
A common purpose
“We are excited to join forces with Nestlé Health Science, and we share their commitment to personalised nutrition,” said Eric Wingerter, Pamlab President and Chief Executive Officer.
“With their support, we will accelerate the development and deployment of our innovative nutritional solutions for people with chronic metabolic and neurologic conditions.
“We are united by a common purpose, and a common culture, founded on our passion for patients to make a difference in people’s lives.”
Building on ambition towards science-based nutritional solutions
Nestlé Health Science’s core business provides nutritional solutions for people with specific dietary needs related to illness or disease states in the area of ageing medical care, critical care and surgery, and paediatric medical care.
The company is also developing new approaches to chronic diseases in the areas of gastrointestinal (GI) health, metabolic health and brain health.
In 2012 Nestlé Health Science agreed to form a 50/50 joint venture named Nutrition Science Partners, Ltd to develop nutritional and medicinal products derived from plants to address gastrointestinal disorders. This transaction is subject to regulatory approval.
Other acquisitions and partnerships include: Prometheus Laboratories, a US firm specialising in diagnostics and licensed speciality pharmaceuticals in GI and oncology; Vitaflo, a provider of clinical nutritional solutions for infants, children and adults with genetic disorders that affect how food is processed by the body; and a minority investment in US firm Accera, specialising in medical foods intended for the clinical dietary management of mild to moderate Alzheimer’s disease.
Terms of acquisition
The terms of Nestlé Health Science’s acquisition of Pamlab are not being disclosed. The transaction is subject to regulatory approval.
Original source: http://www.nestle.com/media/newsandfeatures/nhsc-acquires-pamlab
Chinese infant formula maker Beingmate has announced plans to invest a total of CNY155m (US$25.4m) in the construction of a large-scale dairy farm....
- Why Jet.com purchase could boost Wal-Mart online
- Murray Goulburn's FY results - 7 things to learn
- Nestle on China, candy, nutrition - analysis
- Interview, part 1: Emmi CEO Urs Riedener
- England child obesity plan should cheer industry
- Mondelez buys rest of Vietnam snacks business
- Australia launches dairy sector probe
- Tyson faces investor scrutiny on ethical issues
- Nomad Foods touts progress as H1 results worsen
- Mengniu grows sales but net profit slips